DDInter596 DDInter170
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affect DNA gyrase; instead, bedaquiline inhibits the c subunit of ATP synthase responsible for synthesizing ATP. Consequently, bedaquiline can be used to treat mycobacterial infection, particularly tuberculosis (TB). Although the current standard of TB treatment of anti-TB drugs for 2 months, including 2 key drugs [isoniazid] and [rifampin], is highly effective, the emergence of multidrug-resistant TB (MDR-TB) to [isoniazid] and [rifampin] has substantially worsened patients outcome. Bedaquiline was approved by the FDA on December 28, 2012, to treat pulmonary MDR-TB, following favorable results in multiple pre-clinical and clinical studies.[A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market. Currently, bedaquiline is the last-line anti-TB drug and must only be used in an appropriate combination regimen.[L48506,A261866]
Doxorubicin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bedaquiline
Doxorubicin {u} (Compound) causes {v} (Side Effect) Arrhythmia
Arrhythmia {u} (Side Effect) is caused by {v} (Compound) Bedaquiline
Doxorubicin {u} (Compound) resembles {v} (Compound) Epirubicin
Epirubicin {u} may lead to a major life threatening interaction when taken with {v} Bedaquiline
Doxorubicin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Orphenadrine
Orphenadrine {u} (Compound) resembles {v} (Compound) Bedaquiline
Doxorubicin {u} (Compound) causes {v} (Side Effect) Arrhythmia
Arrhythmia {u} (Side Effect) is caused by {v} (Compound) Ibuprofen
Ibuprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bedaquiline
Doxorubicin {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Afatinib
Afatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bedaquiline
Doxorubicin {u} (Compound) causes {v} (Side Effect) Hepatobiliary disease
Hepatobiliary disease {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bedaquiline
Doxorubicin {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Diphenhydramine
Diphenhydramine {u} (Compound) resembles {v} (Compound) Bedaquiline
Doxorubicin {u} (Compound) resembles {v} (Compound) Epirubicin
Epirubicin {u} (Compound) causes {v} (Side Effect) Arrhythmia
Arrhythmia {u} (Side Effect) is caused by {v} (Compound) Bedaquiline
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bedaquiline
Doxorubicin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bedaquiline (Compound)
Doxorubicin (Compound) causes Arrhythmia (Side Effect) and Arrhythmia (Side Effect) is caused by Bedaquiline (Compound)
Doxorubicin (Compound) resembles Epirubicin (Compound) and Epirubicin may lead to a major life threatening interaction when taken with Bedaquiline
Doxorubicin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Orphenadrine (Compound) and Orphenadrine (Compound) resembles Bedaquiline (Compound)
Doxorubicin (Compound) causes Arrhythmia (Side Effect) and Arrhythmia (Side Effect) is caused by Ibuprofen (Compound) and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Doxorubicin (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Afatinib (Compound) and Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Doxorubicin (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobiliary disease (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bedaquiline
Doxorubicin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Diphenhydramine (Compound) and Diphenhydramine (Compound) resembles Bedaquiline (Compound)
Doxorubicin (Compound) resembles Epirubicin (Compound) and Epirubicin (Compound) causes Arrhythmia (Side Effect) and Arrhythmia (Side Effect) is caused by Bedaquiline (Compound)
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bedaquiline (Compound)